Ignite Creation Date:
2024-07-17 @ 10:46 AM
Last Modification Date:
2024-10-26 @ 3:32 PM
Study NCT ID:
NCT06472440
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-25
First Post:
2024-05-17
Brief Title:
Evaluation of the Use of a Method Radiomics for DOPA PET in Gliomas
Sponsor:
Central Hospital Nancy France
Organization:
Central Hospital Nancy France
Study Overview
Official Title:
Evaluation of the Use of a Method Radiomics for Positons Emission Tomography With Fluor-18-Fluoro-DOPA PET in Gliomas
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
RADDOPAG-2
Brief Summary:
The evaluation of gliomas in imaging represents a real challenge today at the initial diagnosis for therapeutic planning or follow-up treatment of these lesions There is an urgent need for non-invasive imaging tools to evaluate a glioma throughout its management At present the diagnosis of certainty is only obtained through an anatomo-pathological analysis with sampling during an invasive procedure surgery or biopsy Magnetic resonance imaging through perfusion diffusion imaging or spectroscopy is developing in gliomas However it remains time-consuming and is not always available At the same time positron emission tomography PET with amino acids is an interesting alternative for these brain tumours Amino acid PET has the advantage of being more specific than the abnormalities detected in MRI and the amino acid radiotracers cross the blood-brain barrier even if not broken unlike Gadolinium in MRI Among these radiotracers 18F-FDOPA can among other things assist in the non-invasive staging of gliomas at initial diagnosis
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None